TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01920737
Drug: PEG-Asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01920737
Drug: 6-MP (6-Mercaptopurine)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01920737
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01282151
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
Study: NCT01282151
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
Study: NCT04524897
Drug: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
Study: NCT00569881
Drug: gatifloxacin and moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of wound healing between drugs
Study: NCT00194597
Drug: Viagra (sildenafil citrate)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00388960
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.
Study: NCT00388960
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT00388960
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT00040365
Drug: Amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
Study: NCT04360629
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid will be given through central vein
Study: NCT01137695
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mcg SQ three times daily for 6 months.
Study: NCT01137695
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 360 mcg SQ three times daily for 6 months
Study: NCT01137695
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mcg SQ three times daily for 6 months
Study: NCT00770510
Drug: Eszopiclone 1 mg
Normalized name: eszopiclone 1 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study: NCT00770510
Drug: Eszopiclone 2 mg
Normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study: NCT00770510
Drug: Eszopiclone 3 mg
Normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study: NCT00770510
Drug: Zolpidem Tartrate 10 mg
Normalized name: zolpidem tartrate 10 MG
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Study: NCT00556049
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Study: NCT00556049
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally on days 1-14 of each 21-day treatment cycle
Study: NCT01920737
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00571428
Drug: Arformoterol Tartrate Inhalation Solution
Normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
Study: NCT00571428
Drug: Arformoterol Tartrate Inhalation Solution
Normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
Study: NCT01818856
Drug: Ritonavir withdrawal, atazanavir 200 mg/12h
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01818856
Drug: Telaprevir interactions
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02705820
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch maintenance pembrolizumab treatment
Study: NCT03048162
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 ml of 0.9% isotonic sodium chloride
Study: NCT03048162
Drug: Hydroxyethylstarch
Normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 6% Hydroxyethylstarch
Study: NCT03048162
Drug: Ringer-Lactate Infusion Solution Bag
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of Ringer-Lactate Infusion Solution Bag
Study: NCT00526968
Drug: EVT 101
Normalized name: EVT-101
DrugBank: EVT-101 (DB05956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg capsule, single oral dose
Study: NCT00526968
Drug: EVT 101
Normalized name: EVT-101
DrugBank: EVT-101 (DB05956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg capsule, single oral dose
Study: NCT03164772
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PD-L1
Study: NCT03164772
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CTLA-4
Study: NCT02831569
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT02831569
Drug: Methocarbamol
Normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03145714
Drug: Maintainance of anesthesia with Intravenous Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
Study: NCT03145714
Drug: Maintainance of anesthesia with Intravenous Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
Study: NCT02778919
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632136
Drug: TAP Block Group
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
Study: NCT02632136
Drug: Peri-Portal Block Group
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
Study: NCT02596334
Drug: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg
Normalized name: abacavir / dolutegravir / lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02596334
Drug: dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04099888
Drug: Fimaporfin and Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
Study: NCT01215409
Drug: Vardenafil (Levitra, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
Study: NCT00813306
Drug: AZD2066
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg oral solution, 1 single dose
Study: NCT00813306
Drug: AZD2066
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
Study: NCT03604198
Drug: relacorilant
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125134 is supplied as capsules for oral dosing.
Study: NCT00013546
Drug: TMTDS
Normalized name: TMTM
DrugBank: Tetramethylthiuram monosulfide (DB14178)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04705142
Drug: MgSo4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
Study: NCT02238366
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
Study: NCT02677532
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g every 8 hours
Study: NCT02677532
Drug: Levobupivacaine wound infiltration
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wound infiltration with 10 ml levobupivacaine 0.5%
Study: NCT02677532
Drug: Levobupivacaine epidural bolus
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural bolus of 10 ml 0.25% levobupivacaine
Study: NCT02388048
Drug: Ibrutinib + ofatumumab
Normalized name: Ofatumumab
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03805477
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
Study: NCT03629925
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, Q3W, day1, I.V.; consecutive cycles
Study: NCT03629925
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
Study: NCT03629925
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study: NCT03629925
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Study: NCT03504163
Drug: Pembrolizumab (MK-3475)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
Study: NCT03387761
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg
Study: NCT03387761
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg
Study: NCT02677532
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous slow bolus of 10 mg morphine
Study: NCT02677532
Drug: Levobupivacaine plus sufentanil epidural infusion
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
Study: NCT02677532
Drug: Levobupivacaine wound infusion
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
Study: NCT00430079
Drug: etanidazole
Normalized name: Etanidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00802100
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tablets of 10 to 30 mg
Study: NCT00802100
Drug: Perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tablets of 8 to 24 mg
Study: NCT00802100
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily tablets of 10 to 30 mg
Study: NCT00802100
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily tablets of 850 to 2550 mg
Study: NCT00802100
Drug: Benztropine
Normalized name: Benztropine
DrugBank: Benzatropine (DB00245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tablets of 1 to 2 mg
Study: NCT02283775
Drug: Isatuximab SAR650984
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT03499704
Drug: Pioglitazone + Alogliptin
Normalized name: alogliptin / pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone and Alogliptin FDC tablets
Study: NCT03499704
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets.
Study: NCT03499704
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets.
Study: NCT03499704
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin tablets.
Study: NCT02283775
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:capsules Route of administration: oral
Study: NCT02283775
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
Study: NCT02024087
Drug: Dalantercept plus sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
Study: NCT04506242
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1
Study: NCT04506242
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR2
Study: NCT00043771
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03614364
Drug: herzuma
Normalized name: Herzuma
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
Study: NCT00261469
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00091442
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
Study: NCT00091442
Drug: DOXIL
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Study: NCT00092989
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of Treatment: 1 dose
Study: NCT04377620
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinb administered BID approximately 12 hours apart
Study: NCT04312204
Drug: Sintilimab combined with Gemcitabine and Carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months.
Study: NCT02252913
Drug: Volitinib
Normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02252913
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT02997800
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
Study: NCT02997800
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study: NCT00495365
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04190693
Drug: IMCY-0098 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Long-term follow-up